证券代码：688176 证券简称：亚虹医药 公告编号：2026-002 江苏亚虹医药科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）于 2026 年 1 月 16 日召开第二届董事会第二十次会议，审议通过了《关于使用部分 暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集资金投资 项目实施、募集资金安全的前提下，使用部分暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、具有合法经营资格的金融机构销售 的投资产品，使用期限自本次董事会审议通过之日起 12 个月内有效，在前述额 度及期限范围内，公司可以循环滚动使用。 董事会授权董事长在授权额度和期限内行使现金管理投资决策权并签署相 关合同文件，具体事项由公司财务部负责组织实施。保荐人中信证券股份有限公 司（以下简称"保荐人"）对上述事项出具了核查意见。本事项无需提交股东会 审议。现将公司本次使用部分闲置募集资金进行现金管 ...

中信证券股份有限公司关于江苏亚虹医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）为江苏亚虹 医药科技股份有限公司（以下简称"公司"、"亚虹医药"）首次公开发行股票 并上市的保荐人。根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》等相关法律、法规和规范性文件的规定， 对亚虹医药使用部分暂时闲置募集资金进行现金管理事项进行了核查，核查情况 及核查意见如下： 一、募集资金基本情况 （三）资金来源 | 发行名称 | 公司首次公开发行股票 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 募集资金到账时间 | 2021 年 12 月 31 | | | 日 | | | | | | 募集资金总额 | 252,780.00 | | 万元 | | | | | | | 募集资金净额 | 万元 238,059.22 | | | | | | ...

Core Viewpoint - The company, Yahuang Pharmaceutical, has announced the approval of a proposal to use up to 1.2 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [1] Group 1: Financial Management - The board of directors approved the use of idle funds for cash management, with a maximum limit of 1.2 billion yuan [1] - The investment products will be purchased from financial institutions that offer high safety, good liquidity, and capital protection agreements [1] - The usage period for these funds is valid for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] Group 2: Impact on Operations - This decision will not affect the progress of the fundraising investment projects or the normal production and operation of the company [1]

Group 1 - The chemical pharmaceutical sector experienced a decline of 1.4% on January 15, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] - Notable gainers in the chemical pharmaceutical sector included Shanhe Pharmaceutical with a closing price of 16.85, up 20.01%, and Duorui Pharmaceutical at 62.71, up 11.48% [1] Group 2 - Sunflower saw a significant drop of 20.00%, closing at 4.96, with a trading volume of 357,900 shares and a turnover of 178 million [2] - The sector faced a net outflow of 1.656 billion from major funds, while retail investors contributed a net inflow of 1.46 billion [2] - The top individual stock in terms of net inflow from major funds was Shanhe Pharmaceutical, with a net inflow of 1.56 billion [3]

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. has completed the first subject enrollment in the Phase I clinical trial of APL-2401, a selective FGFR2/3 dual-target small molecule inhibitor for advanced solid tumors [2][4]. Group 1: Drug Information - APL-2401 is a high-selectivity small molecule inhibitor targeting FGFR2/3, potentially providing a new treatment option for patients with advanced solid tumors such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [2][3]. - The drug was optimized through the TAIDD platform, demonstrating superior dual kinase inhibition activity and reduced side effects compared to existing FGFR2 or FGFR3 selective inhibitors [3]. Group 2: Clinical Trial and Regulatory Approval - APL-2401 is a globally developed Class 1 innovative drug, with its clinical trial design and submission materials meeting international standards. It was approved by the National Medical Products Administration (NMPA) in just 22 working days, becoming one of the first projects to benefit from the new regulatory policy [4]. - The first administration of the drug occurred only 15 working days after approval, marking it as one of the projects that significantly benefited from the expedited clinical development process [4].

Core Viewpoint - Aihong Pharmaceutical (688176) has announced the completion of the first patient enrollment in a Phase I clinical trial for its self-developed drug APL-2401, targeting FGFR2/3-driven advanced solid tumors [1] Group 1 - APL-2401 is a highly selective small molecule inhibitor targeting fibroblast growth factor receptors 2 and 3 (FGFR2/3) [1] - The drug aims to provide a new treatment option for patients with advanced solid tumors, including urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [1]

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

证券代码：688176 证券简称：亚虹医药 公告编号：2026-001 二、该药品研发及其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）自主研发的 APL-2401 在 FGFR2/3 驱动的晚期实体瘤患者中开展的 I 期临床试验（以下简称 "该研究"）完成首例受试者入组。现就相关情况公告如下： 一、药品基本情况 APL-2401 是公司自主研发的高选择性成纤维生长因子受体 2/3（FGFR2/3） 双靶点小分子抑制剂，有望为晚期实体瘤（例如：尿路上皮癌、胆管癌、子宫内 膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤）患者提供一种 新的治疗选择。 公司通过 TAIDD 平台进行靶点多构象模拟，并以其选择性机制作为苗头化 合物发现和设计为核心，从而优化出最终的临床前候选化合物 APL-2401。 APL-2401 是一款通过非共价结合模式与靶点相结合的高选择性的 FGFR2/3 小分 子抑制剂。相比现阶段 FGFR2 或 FGFR3 ...

Core Viewpoint - The company, Yahui Pharmaceutical, has announced the completion of the first patient enrollment in a Phase I clinical trial for its self-developed drug APL-2401, targeting advanced solid tumors driven by FGFR2/3 [1] Group 1: Drug Development - APL-2401 is a highly selective small molecule inhibitor targeting fibroblast growth factor receptors 2 and 3 (FGFR2/3) [1] - The drug aims to provide a new treatment option for patients with advanced solid tumors, including urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [1]

Core Viewpoint - The company has announced the completion of the first patient enrollment in a Phase I clinical trial for its self-developed APL-2401, a dual-target small molecule inhibitor for FGFR2/3, aimed at providing new treatment options for patients with advanced solid tumors [1] Group 1 - APL-2401 is a highly selective small molecule inhibitor targeting fibroblast growth factor receptors 2 and 3 (FGFR2/3) [1] - The clinical trial focuses on patients with advanced solid tumors driven by FGFR2/3 [1] - The development of APL-2401 represents a potential new therapeutic choice for this patient population [1]